Goldfinch Bio

OverviewSuggest Edit

Goldfinch is singularly focused on discovering and developing precision therapies for patients with kidney disease.Chronic kidney disease is a driver of mortality across age, race, and stage of disease progression, affecting over 1 in 9 people worldwide. It has emerged as a global epidemic and growing problem that places an enormous social and economic burden on patients, their families, and society.Advances in kidney transplantation and dialysis over half a century ago extended life for patients with kidney failure, yet the current standard of care for patients with kidney disease remains inadequate, and there is an urgent need for new treatment options.Recent breakthroughs in genetics and biology have generated an unparalleled understanding of the biological pathways that drive kidney disease. Goldfinch is uniquely positioned to translate these discoveries into new therapies that target the molecular causes of kidney disease.

HQCambridge, US

Key People/Management at Goldfinch Bio

Anthony Johnson

Anthony Johnson

Chief Executive Officer, Director
Frank S. Czerwiec

Frank S. Czerwiec

Chief Medical Officer
Peter Mundel

Peter Mundel

Founder and Advisor
Jean-Christophe Harmange

Jean-Christophe Harmange

Senior Vice President of Drug Discovery
Lori Rudolph-Owen

Lori Rudolph-Owen

Senior Vice President, R&D Strategy and Operations
Curtis Demick

Curtis Demick

Vice President of Human Resources
Show more

Goldfinch Bio Office Locations

Goldfinch Bio has an office in Cambridge
Cambridge, US (HQ)
215 First St 4th floor
Show all (1)

Goldfinch Bio Financials and Metrics

Summary Metrics

Goldfinch Bio total Funding

$55 m

Goldfinch Bio latest funding size

$55 m

Time since last funding

3 years ago
Goldfinch Bio's latest funding round in December 2016 was reported to be $55 m. In total, Goldfinch Bio has raised $55 m
Show all financial metrics

Goldfinch Bio Online and Social Media Presence

Embed Graph

Goldfinch Bio News and Updates

Gilead Sciences and Goldfinch Bio Announce Strategic Collaboration to Develop Novel Therapies for Kidney Disease

Gilead Sciences, Inc. (Nasdaq: GILD) and Goldfinch Bio, Inc., a biotechnology company focused on developing precision therapies for patients with kidney diseases, today announced a strategic collaboration to discover, develop and commercialize a pipeline of innovative therapeutics for diabetic kidne…

Gilead strikes deal with biotech Goldfinch Bio to tackle kidney diseases

Gilead Sciences Inc. and biotech Goldfinch Bio Inc. are striking a deal to develop and commercialize a pipeline of drugs for kidney diseases, the companies announced Wednesday. Under the terms of the deal, Goldfinch will receive $55 million up front, including a $5 million equity investment, and a…

Goldfinch Bio Frequently Asked Questions

  • Who are Goldfinch Bio key executives?

    Goldfinch Bio's key executives are Anthony Johnson, Frank S. Czerwiec and Peter Mundel.

  • Who are Goldfinch Bio competitors?

    Competitors of Goldfinch Bio include Ginkgo Bioworks, Verona Pharma and Rapid Micro Biosystems.

  • Where is Goldfinch Bio headquarters?

    Goldfinch Bio headquarters is located at 215 First St 4th floor, Cambridge.

  • Where are Goldfinch Bio offices?

    Goldfinch Bio has an office in Cambridge.

  • How many offices does Goldfinch Bio have?

    Goldfinch Bio has 1 office.